Endoglin for targeted cancer treatment topical collection on evolving therapies

Lee S. Rosen, Michael S. Gordon, Francisco Robert, Daniela Matei

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody-drug conjugate is also described.

Original languageEnglish
Article number365
JournalCurrent Oncology Reports
Volume16
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Sarcoma
Endothelial Cells
Therapeutics
Bone Morphogenetic Proteins
Antibodies
Membrane Glycoproteins
Transforming Growth Factors
Renal Cell Carcinoma
Hepatocellular Carcinoma
Cell Membrane
Endoglin
TRC105
Pharmaceutical Preparations
Bevacizumab
Hypoxia
In Vitro Techniques

Keywords

  • Angiogenesis
  • Antibody
  • Antibody-drug conjugate
  • Bone morphogenic protein
  • CD105
  • Endoglin
  • Glioblastoma
  • Hepatocellular cancer
  • Hypoxia
  • Prostate cancer
  • Radioimmunoconjugate
  • Renal cell cancer
  • Sarcoma
  • Transforming growth factor β
  • TRC105
  • Vascular endothelial growth factor resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Endoglin for targeted cancer treatment topical collection on evolving therapies. / Rosen, Lee S.; Gordon, Michael S.; Robert, Francisco; Matei, Daniela.

In: Current Oncology Reports, Vol. 16, No. 2, 365, 2014.

Research output: Contribution to journalArticle

Rosen, Lee S. ; Gordon, Michael S. ; Robert, Francisco ; Matei, Daniela. / Endoglin for targeted cancer treatment topical collection on evolving therapies. In: Current Oncology Reports. 2014 ; Vol. 16, No. 2.
@article{205b231a06334c47aff05c683df2b969,
title = "Endoglin for targeted cancer treatment topical collection on evolving therapies",
abstract = "Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody-drug conjugate is also described.",
keywords = "Angiogenesis, Antibody, Antibody-drug conjugate, Bone morphogenic protein, CD105, Endoglin, Glioblastoma, Hepatocellular cancer, Hypoxia, Prostate cancer, Radioimmunoconjugate, Renal cell cancer, Sarcoma, Transforming growth factor β, TRC105, Vascular endothelial growth factor resistance",
author = "Rosen, {Lee S.} and Gordon, {Michael S.} and Francisco Robert and Daniela Matei",
year = "2014",
doi = "10.1007/s11912-013-0365-x",
language = "English",
volume = "16",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Endoglin for targeted cancer treatment topical collection on evolving therapies

AU - Rosen, Lee S.

AU - Gordon, Michael S.

AU - Robert, Francisco

AU - Matei, Daniela

PY - 2014

Y1 - 2014

N2 - Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody-drug conjugate is also described.

AB - Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody-drug conjugate is also described.

KW - Angiogenesis

KW - Antibody

KW - Antibody-drug conjugate

KW - Bone morphogenic protein

KW - CD105

KW - Endoglin

KW - Glioblastoma

KW - Hepatocellular cancer

KW - Hypoxia

KW - Prostate cancer

KW - Radioimmunoconjugate

KW - Renal cell cancer

KW - Sarcoma

KW - Transforming growth factor β

KW - TRC105

KW - Vascular endothelial growth factor resistance

UR - http://www.scopus.com/inward/record.url?scp=84899435362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899435362&partnerID=8YFLogxK

U2 - 10.1007/s11912-013-0365-x

DO - 10.1007/s11912-013-0365-x

M3 - Article

VL - 16

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

M1 - 365

ER -